Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alniditan SCHEMBL29412188 | 1.00 | HTR1A (1.00) | HTR1AHTR1D | |
| Alniditan SCHEMBL717888 | 1.00 | HTR1A (1.00) | HTR1AHTR1D | |
| Alniditan SCHEMBL7918202 | 0.99 | HTR1A (0.98) | HTR1AHTR1D | |
| Alniditan SCHEMBL7918206 | 0.99 | HTR1A (0.98) | HTR1AHTR1D | |
| Alniditan SCHEMBL8864173 | 0.98 | HTR1A (0.96) | HTR1AHTR1D | |
| Alniditan SCHEMBL8864171 | 0.98 | HTR1A (0.96) | HTR1AHTR1D | |
| SCHEMBL8886279 | 0.86 | HTR1A (0.75) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL8886666 | 0.85 | HTR1A (0.74) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL8043639 | 0.83 | HTR1A (0.89) | HTR1AHTR1D | |
| Oxalic Acid SCHEMBL8864589 | 0.82 | HTR1A (0.73) | HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-11478476-B2 | Use of buspirone metabolites | CONTERA PHARMA APS (DK) | 2022-10-25 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3897641-A1 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma A/S (DK) | 2021-10-27 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| WO-2020127954-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2020-06-25 | — | — | WO | claimed |
| EP-3160464-B1 | 6-HYDROXYBUSPIRONE FOR USE IN THE TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2018-07-18 | — | — | EP | claimed |
| CN-1832758-A | Pharmaceutical composition | GLAXO GROUP LTD (GB) | 2006-09-13 | — | — | CN | claimed |
| EP-1633402-A2 | PHARMACEUTICAL COMPOSITION | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | claimed |
| WO-2004110492-A2 | COMPOSITION COMPRISING TRIPTANS AND NSAIDS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | claimed |
| EP-1239878-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT1 AGONISTS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030004127-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | claimed |
| EP-1239878-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045682-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004127-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA2A, ADORA3 | HTR1A 5/4885HTR1D 7/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885HTR1D 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.